

Article title: Understanding Heterogeneous Drug Procurement Behaviour of Healthcare Institutions Under Pooled Procurement: Evidence From China

Journal name: International Journal of Health Policy and Management (IJHPM)

Authors' information: Boya Zhao, Zhao Cheng, Xing Lin Feng*

School of Public Health, Peking University, Beijing, China.

***Correspondence to:** Xing Lin Feng; Email: fxl@bjmu.edu.cn

Citation: Zhao B, Cheng Z, Feng XL. Understanding heterogeneous drug procurement behaviour of healthcare institutions under pooled procurement: evidence from China. Int J Health Policy Manag. 2026;15:9372. doi:[10.34172/ijhpm.9372](https://doi.org/10.34172/ijhpm.9372)

Supplementary file 2

List of contents

Figure S1. Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Five-Level Stratification)3

Figure S2. Sensitivity Analyses: Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Three-Level Stratification)4

Figure S3. Sensitivity Analyses: Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Median Split).....4

Figure S4. Sensitivity Analyses: Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Mean Split).....4

Figure S5. Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Five-Level Stratification)5

Figure S6. ITS-Based Forest Plot of Post-Policy Changes in Alternative Drug Procurement Volume by Pre-Policy NVBP Share (Stratified in 0.05 and 0.01 increments)6

Figure S7. Sensitivity Analyses: Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Three-Level Stratification)6

Figure S8. Sensitivity Analyses: Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Median Split).....7

Figure S9. Sensitivity Analyses: Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Mean Split).....7

Figure S10. ITS-Based Forest Plot of Post-Policy Changes in Alternative Drug Procurement Volume by Pre-Policy NVBP Share for the three alternative drug categories8

Figures




Figure S1. Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Five-Level Stratification)




Figure S2. Sensitivity Analyses: Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Three-Level Stratification)




Figure S3. Sensitivity Analyses: Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Median Split)




Figure S4. Sensitivity Analyses: Estimated Trends from ITS on Bid-Winning Product Procurement by Pre-Policy Bid-Winning Share (Mean Split)




Figure S5. Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Five-Level Stratification)




Figure S6. ITS-Based Forest Plot of Post-Policy Changes in Alternative Drug Procurement Volume by Pre-Policy NVBP Share (Stratified in 0.05 and 0.01 increments)

Note: The figure only displays estimated post-policy level changes (β_2) and their 95% confidence intervals from ITS regressions. Trend changes (β_3) are not shown, as they were consistently insignificant.






Figure S7. Sensitivity Analyses: Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Three-Level Stratification)




(a) Low Share Subgroup




(b) High Share Subgroup

Figure S8. Sensitivity Analyses: Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Median Split)




(a) Low Share Subgroup




(b) High Share Subgroup

Figure S9. Sensitivity Analyses: Estimated Trends from ITS on Alternative Drug Procurement by Pre-Policy NVBP Share (Mean Split)

(a) Procurement of Alternative drugs: Completely substitutable (Tier-1)



(b) Procurement of Alternative drugs: Largely substitutable (Tier-2)



(c) Procurement of Alternative drugs: Partially substitutable (Tier-3)




Figure S10. ITS-Based Forest Plot of Post-Policy Changes in Alternative Drug Procurement Volume by Pre-Policy NVBP Share for the three alternative drug categories

Note: The figure only displays estimated post-policy level changes (β_2) and their 95% confidence intervals from ITS regressions. Trend changes (β_3) are not shown, as they were consistently insignificant.